Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Investing

Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial

admin by admin
April 17, 2025
in Investing
0
Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing in the fast-growing market for weight loss and diabetes treatments.

The results, announced Thursday, show the pill could offer a compelling, needle-free alternative to popular injections, potentially reshaping how millions of people manage chronic conditions.

Shares of Eli Lilly rose as much as 11% in premarket trading on Thursday as investors welcomed the results, which put the company a step ahead of rivals such as Novo Nordisk in developing an oral version of the lucrative GLP-1 class of drugs.

The US pharmaceutical giant reported that orforglipron helped patients with Type 2 diabetes achieve both weight loss and improved blood sugar control.

The trial, one of seven late-stage studies underway, also found the pill’s side effect profile to be largely manageable and in line with what is observed in injectable drugs already on the market.

A promising alternative to injections

At its highest dose, orforglipron led to an average weight loss of 7.9% — roughly 16 pounds — over 40 weeks.

Notably, patients had not plateaued in their weight loss by the end of the study, suggesting that longer treatment may yield further results.

This development is significant for patients seeking a more convenient alternative to injectables like Wegovy and Ozempic.

Pills are easier to manufacture and distribute at scale, which could help alleviate the persistent supply shortages that have plagued the market for injectable GLP-1 drugs.

CEO David Ricks emphasized the potential impact in a company statement:

We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control, and weight loss. We look forward to additional data readouts later this year.”

Safety is in line with expectations

Side effects were mostly mild to moderate, with gastrointestinal symptoms such as nausea, vomiting, and diarrhea reported.

Around 8% of patients on the highest dose discontinued treatment due to side effects, which analysts say is within an acceptable range.

In comparison, injectable versions of the drug class tend to have similar or slightly lower discontinuation rates, though they are administered weekly rather than daily.

Analysts had expected discontinuation rates around 9%, indicating that the results came in close to forecast.

TD Cowen and other investment firms had anticipated that side effects could be marginally worse with a daily oral pill.

Mixed results on diabetes metric

Despite positive signs, orforglipron fell short of some analyst expectations when it came to lowering hemoglobin A1c, a key diabetes marker.

The pill reduced blood sugar levels by 1.3% to 1.6% across doses after 40 weeks, from a starting level of 8%.

This compares with reductions as high as 2.1% seen in some patients using Novo Nordisk’s injection Ozempic.

The result remains clinically meaningful, but the gap could influence prescribing patterns if physicians view injections as more effective for glucose control.

Still, the pill’s ease of use may be enough to offset that in patients prioritizing convenience.

Looking ahead to regulatory filings

Eli Lilly plans to file for regulatory approval for orforglipron in obesity by the end of 2025, with a diabetes filing expected in 2026.

The company is currently conducting five trials in diabetes and two in obesity, with more data expected later this year.

The pill is not a peptide-based drug, meaning it is absorbed more easily by the body and doesn’t require food restrictions, unlike Novo Nordisk’s diabetes pill Rybelsus.

This could make it more appealing to a broader patient population.

Analysts forecast the GLP-1 market could exceed $150 billion annually by the early 2030s, with oral drugs accounting for up to $50 billion.

Eli Lilly, already a leader with injectable drugs like Mounjaro, may solidify its dominance if orforglipron gains approval.

With its lead over competitors including AstraZeneca, Roche, Structure Therapeutics, and Viking Therapeutics, Eli Lilly is positioning itself to be the first to offer a widely available oral GLP-1 therapy — and reshape the landscape of chronic disease management.

The post Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial appeared first on Invezz

Previous Post

Bill Ackman raises stake in Hertz: here’s why I’m not as optimistic

Next Post

Sainsbury’s shares rise as profit tops £1bn; analysts flag cautious guidance amid price war risks

admin

admin

Next Post
Sainsbury’s shares rise as profit tops £1bn; analysts flag cautious guidance amid price war risks

Sainsbury’s shares rise as profit tops £1bn; analysts flag cautious guidance amid price war risks

Trending News

As Biden nears exit, US bans medical debt from credit reports

As Biden nears exit, US bans medical debt from credit reports

January 7, 2025
Fed seen cutting policy rate just once in 2025 as job growth surges

Fed seen cutting policy rate just once in 2025 as job growth surges

January 10, 2025
XRP Holders Watch in Silence as Ozak AI Presale Dominates 2025 Crypto Buzz

XRP Holders Watch in Silence as Ozak AI Presale Dominates 2025 Crypto Buzz

August 5, 2025
Subscribe to Insightful Word


    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025
    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    August 28, 2025
    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    August 28, 2025

    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025

    Latest News

    • Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in
    • SentinelOne stock price forecast ahead of earnings: buy or sell?
    • Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.